one8zero8 LLC bought a new stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,000 shares of the company's stock, valued at approximately $267,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in DOCS. FMR LLC increased its stake in shares of Doximity by 30.5% in the third quarter. FMR LLC now owns 6,837,733 shares of the company's stock valued at $297,920,000 after buying an additional 1,598,602 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Doximity in the third quarter valued at $29,453,000. Wilmington Savings Fund Society FSB acquired a new stake in Doximity in the third quarter worth about $24,691,000. Geode Capital Management LLC increased its position in Doximity by 19.8% in the third quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company's stock worth $124,503,000 after purchasing an additional 472,565 shares during the period. Finally, Retirement Systems of Alabama increased its position in Doximity by 254.3% in the third quarter. Retirement Systems of Alabama now owns 534,256 shares of the company's stock worth $23,278,000 after purchasing an additional 383,480 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
DOCS has been the subject of a number of research reports. Wells Fargo & Company reiterated an "equal weight" rating on shares of Doximity in a research report on Friday, February 7th. Stephens initiated coverage on Doximity in a research report on Friday, December 20th. They issued an "equal weight" rating and a $55.00 price objective for the company. Bank of America lifted their price objective on Doximity from $54.00 to $57.00 and gave the stock a "neutral" rating in a research report on Monday, January 6th. JPMorgan Chase & Co. lifted their price objective on Doximity from $30.00 to $48.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Finally, Piper Sandler upgraded Doximity from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $31.00 to $78.00 in a research report on Friday, February 7th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $64.22.
Check Out Our Latest Stock Report on DOCS
Doximity Trading Up 0.2 %
Shares of NASDAQ:DOCS traded up $0.15 during trading on Thursday, hitting $62.84. 2,491,456 shares of the company's stock traded hands, compared to its average volume of 1,869,490. Doximity, Inc. has a 52 week low of $22.96 and a 52 week high of $85.21. The company has a market cap of $11.73 billion, a price-to-earnings ratio of 62.84, a price-to-earnings-growth ratio of 4.10 and a beta of 1.34. The company has a 50-day moving average price of $64.04 and a 200-day moving average price of $53.14.
Insider Activity
In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the sale, the director now owns 6,360 shares in the company, valued at approximately $366,463.20. The trade was a 75.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 37.40% of the stock is currently owned by company insiders.
Doximity Company Profile
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Further Reading
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
